Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease

Vista sencilla de ítem
dc.contributor.authorKnox, Aaron J.
dc.contributor.authorScaling, Allison L.
dc.contributor.authorPinto, Mauricio P.
dc.contributor.authorBliesner, Brian S.
dc.contributor.authorHaughian, James M.
dc.contributor.authorAbdel-Hafiz, Hany A.
dc.contributor.authorHorwitz, Kathryn B.
dc.date.accessioned2023-05-31T16:40:35Z
dc.date.available2023-05-31T16:40:35Z
dc.date.issued2014-08
dc.descriptionIndexación: Scopus.es
dc.description.abstractIntroduction: Many Luminal breast cancers are heterogeneous, containing substantial numbers of estrogen (ER) and progesterone (PR) receptor-negative cells among the ER+ PR+ ones. One such subpopulation we call “Luminobasal” is ER-, PR- and cytokeratin 5 (CK5)-positive. It is not targeted for treatment. Methods: To address the relationships between ER+PR+CK5– and ER–PR–CK5+ cells in Luminal cancers and tightly control their ratios we generated isogenic pure Luminal (pLUM) and pure Luminobasal (pLB) cells from the same parental Luminal human breast cancer cell line. We used high-throughput screening to identify pLB-specific drugs and examined their efficacy alone and in combination with hormone therapy in mixed-cell tumor models. Results: We show that pLUM and MCF7 cells suppress proliferation of pLB cells in mixed-cell 3D colonies in vitro and that pLUM cells suppress growth of pLB cells in mixed-cell xenografts in vivo. High-throughput screening of 89 FDA-approved oncology drugs shows that pLB cells are sensitive to monotherapy with the epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib. By exploiting mixed-cell 3D colonies and mixed-cell solid mouse tumors models we demonstrate that combination therapy with gefitinib plus the anti-estrogen fulvestrant constitutes a robust treatment strategy. Conclusions We propose that response to combination endocrine/EGFR inhibitor therapies in heterogeneous Luminal cancers may improve long-term survival in patients whose primary tumors have been preselected for appropriate biomarkers, including ER, PR, CK5 and EGFR.es
dc.description.urihttps://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-014-0418-6#Abs1
dc.identifier.citationBreast Cancer Research. Volume 16, Issue 4. August 13, 2014. Article number 418es
dc.identifier.doiDOI: 10.1186/s13058-014-0418-6
dc.identifier.issn1465-5411
dc.identifier.urihttps://repositorio.unab.cl/xmlui/handle/ria/50178
dc.language.isoenes
dc.publisherBioMed Central Ltd.es
dc.rights.licenseAtribution 4.0 International (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/deed.es
dc.subjectEstrogen Receptores
dc.subjectProgesterone Receptores
dc.subjectGefitinibes
dc.subjectFulvestrantes
dc.subjectIntratumoral Heterogeneityes
dc.titleModeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal diseasees
dc.typeArtículoes
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Knox_A_Modeling_luminal_breast_cancerheterogeneity_Combination_therapy_to.pdf
Tamaño:
1.55 MB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLÉS
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
FM - Artículos de Revista